Skip to main content

Table 1 Selected SNPs in IGF-1 pathway

From: Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

RS number Gene Alleles (major > minor) Position in gene and functionality Clinical influence of polymorphism
rs10735380 IGF1 A > G Transcription factor binding site, intronic Variant G allele associated with increased serum IGF-1 level [20, 35, 41]
rs1520220 IGF1 C > G Intronic Variant G allele associated with increased serum IGF-1 level [35, 42] and BC risk [42].
rs6220 IGF1 A > G 3′-untranslated region, microRNA binding site Variant G allele associated with increased serum IGF-1 level and increased BC risk [42]
rs2946834 IGF1 G > A 3′-untranslated region Variant A allele associated with increased serum IGF-1 level [35, 42] and with worse outcome in BC [21]
rs2270628 IGFBP3 C > T Downstream Variant T allele associated with decreased serum IGF-BP3 level [20, 35, 36]
rs2854746 IGFBP3 G > C Nonsynonymous in exon 1 Variant C allele associated with increased serum IGF-BP3 level [20, 35, 36, 43] and with better outcome in advanced gastric cancer treated with CT [44]
(Ala32Gly)
rs4320932 IGF2 T > C Transcription factor binding site, intronic Variant C allele associated with worse outcome in ovarian cancer and worse response to CT [45]
rs2016347 IGF1R G > T 3′-untranslated region, microRNA binding site Variant T allele associated with better outcome in ER+ BC [22]
  1. SNPs selected on basis of literature research and the clinical influence. rs reference SNP number, BC breast cancer, CT chemotherapy, ER estrogen receptor, IGF insulin-like growth factor, IGFBP3 insulin-like growth factor binding protein 3, IGF1R insulin-like growth factor 1 receptor, SNP single nucleotide polymorphism